Phase 2 Study of MK-2206, an Allosteric Inhibitor of AKT, as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer: A SWOG Cooperative Group Trial (S1005)

BACKGROUND: The AKT inhibitor MK-2206 at a dose of 60 mg every other day was evaluated in gastric/gastroesophageal junction cancers. METHODS: Patients who had progressed after first-line treatment were eligible. Pertinent eligibility criteria included adequate organ function, a fasting serum glucose...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Ramanathan, Ramesh K., McDonough, Shannon L., Kennecke, Hagen F., Iqbal, Syma, Baranda, Joaquina C., Seery, Tara E., Lim, Howard J., Hezel, Aram F., Vaccaro, Gina M., Blanke, Charles D.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4589423/
https://ncbi.nlm.nih.gov/pubmed/25827820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29363
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items